JCAR017 + relatlimab + nivolumab

JCAR017 + relatlimab + nivolumab is a combination therapy consisting of: - **JCAR017 (lisocabtagene maraleucel, liso-cel):** an autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19 on B cells. JCAR017 consists of a precise dose of CD8 and CD4 CAR T cells in a 1:1 ratio, engineered ex vivo with a 4-1BB co-stimulatory domain to promote targeted immune attack of malignant B cells in B-cell non-Hodgkin lymphoma (NHL)[1][2][4][6]. - **Relatlimab:** a human monoclonal antibody targeting lymphocyte activation gene-3 (LAG-3), functioning as an immune checkpoint inhibitor. - **Nivolumab:** a human monoclonal antibody targeting programmed death-1 (PD-1), functioning as an immune checkpoint inhibitor. The primary mechanism is multi-modal immunotherapy: JCAR017 provides engineered T cells to attack malignant B cells, while relatlimab and nivolumab release immune inhibition via LAG-3 and PD-1 blockade, potentially enhancing antitumor immunity.

Brand names

lisocabtagene maraleucel

Other names

liso-celanti-CD19 CAR T-cell therapy + anti–LAG-3 antibody + anti–PD-1 antibody